Skip to main content

Table 1 Asthmatic participants demographics

From: The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study

Participant Gender Age (years) Height (cm) BMI (kg/m2) Mean FEV1/
FVC
Mean Baseline FEV1 (L) Mean Baseline FEV1 (% Predicted) Mean Baseline MCh PC20 (mg/mL)
01 F 24 157 21 0.79 2.24 74 0.24
02 M 40 178 27 0.75 3.49 83 0.92
03 M 20 169 22 0.71 3.61 84 3.6
04 F 28 168 23 0.69 3.32 97 3.8
05 M 27 173 29 0.61 3.14 73 0.22
06 F 23 173 22 0.81 3.55 95 2.0
07 F 21 163 20 0.91 3.70 111 2.4
08 F 21 173 30 0.86 3.65 98 3.7
09 F 29 160 20 0.86 2.62 84 2.0
10 M 32 185 32 0.67 3.41 72 1.8
11 M 70 168 23 0.67 2.14 78 1.7
12 M 22 173 27 0.78 4.17 95 3.1
13 F 18 130 21 0.87 1.62 73 1.3
14 M 25 172 27 0.82 4.23 99 2.1
15 F 30 160 25 0.78 2.98 96 3.2
16 M 23 180 24 0.89 4.29 90 2.4
Means: 50% Male 28 [12] 168 [12] 25 [4] 0.78 [0.09] 3.26 [0.77] 88 [12] 2.2a
  1. BMI body mass index, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, MCh methacholine, PC 20 provocative concentration of MCh causing a 20% fall in FEV1; [], standard deviation;a, geometric mean
  2. Mean Baseline MCh PC20 – determined by averaging the pre-treatment baseline PC20’s